Enosium Life Science, the European life sciences services group backed by Alpera Partners, is pleased to announce the acquisition of RWEality, a recognized consulting and services firm specializing in the evaluation of public policies, healthcare technologies, and medical practices.
A strategic move driven by real-world data expertise
This strategic acquisition marks a key milestone in Enosium Life Science’s growth and supports its ambition to build a multi-specialist group covering the entire healthcare value chain, from clinical development to scientific communication.
Rweality brings extensive expertise in real-world evidence (RWE) and health technology assessment to address critical client needs: market access and pricing strategies, data generation strategies, healthcare system efficiency analysis, patient pathway qualification, and hospital market access.
This acquisition strengthens Enosium Life Science’s activities in market access and health data valuation. The Rweality team adds complementary expertise to Enosium’s existing capabilities in European market access, medical communications, and Health Economics and Outcomes Research (HEOR).
A shared vision and strong synergies
Antoine Amer, Founder and CEO of Enosium Life Science, said:
“I am delighted to welcome Sandrine Bourguignon, a recognized leader and expert in public health and health economics, together with the entire Rweality team. This integration is perfectly aligned with our growth strategy and will accelerate our development and leadership in market access consulting in France and Europe.”
Sandrine Bourguignon, Founder and CEO of Rweality, added:
“Joining Enosium Life Science is a tremendous opportunity for Rweality. Our complementary expertise and shared vision of the market will allow us to accelerate the demonstration of value for our clients’ healthcare products.”
About Enosium Life Science
Founded in January 2024 by Dr. Antoine Amer with the financial backing of Alpera Partners, Enosium Life Science is an integrated scientific services group covering clinical research, regulatory affairs, market access and health economics, medical affairs, marketing, and public affairs for the healthcare industries in Europe. Its mission is to bring together the best expertise across Europe to provide a unique and comprehensive range of scientific services, supporting innovation and excellence in life sciences and enabling faster and broader patient access to medical innovations.
About Rweality
Rweality is a consulting and research firm specialized in real-world data (RWE), Health Economics and Outcomes Research (HEOR), and the evaluation of healthcare technologies and public health policies to support product and business strategies. Its expertise addresses key needs such as market access and pricing, healthcare system analysis, patient pathway qualification, and the creation of innovative solutions to support on-the-ground access.
About Alpera Partners
Working alongside bold entrepreneurs, Alpera Partners creates, develops, and scales the leading groups of tomorrow through roll-up platforms. Each year, Alpera Partners invests more than €80 million in equity to consolidate micro-cap companies in fragmented, high-growth markets and help them grow both organically and through acquisitions. Its focus sectors include healthcare, industry, business services, and real estate.
As of March 2025, Alpera Partners has launched five roll-up platforms in hospitality (Otelium), nuclear (Alfeor), healthcare (Enosium Life Science), accounting services (Archipel), and vertical software (Comet Software). These complement its established platform in veterinary healthcare (Novavet).
.png)